Study on the CHJ01 antitumor activity and mechanism via targeting sphingosine kinase 1 in A549 cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Sphingosine kinase 1 (SphK1) inhibitors are crucial for non-small cell lung cancer (NSCLC) therapy.
• CHJ01 has demonstrated prior anti-tumor properties.

Purpose of the Study:

• To elucidate the detailed anti-tumor mechanisms of CHJ01 in non-small cell lung cancer (NSCLC) both in vitro and in vivo.
• To evaluate CHJ01's potential as a therapeutic candidate for NSCLC.

Main Methods:

• In vitro studies using A549 cells to assess proliferation, migration, invasion, and cytotoxicity.
• Analysis of cell cycle arrest, ceramide levels, and protein expression (TRAF2, Bcl-2, Bax, RELA).
• In vivo studies using a nude mouse ectopic tumor model to evaluate anti-tumor effects.

Main Results:

• CHJ01 significantly inhibited A549 cell proliferation, migration, and invasion, demonstrating cytotoxicity.
• CHJ01 induced G0/G1 cell cycle arrest, increased ceramide levels, and modulated TRAF2/NF-κB signaling.
• Downregulation of Bcl-2 and upregulation of Bax by CHJ01 promoted apoptosis.
• In vivo, CHJ01 reduced xenograft tumor volume and weight, inducing apoptosis.

Conclusions:

• CHJ01 exhibits potent anti-tumor effects against non-small cell lung cancer (NSCLC) through mechanisms involving cell cycle arrest and apoptosis induction.
• CHJ01 effectively inhibits tumor growth in vivo.
• CHJ01 represents a promising therapeutic candidate for NSCLC treatment.